Company news

Sangamo Therapeutics, Inc. news in 2022

Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results

November 2, 2022

Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast

October 26, 2022

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients

October 11, 2022

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated α-gal A Enzyme Activity in Five Longest Treated Patients

August 29, 2022

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results

August 3, 2022

Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast

July 27, 2022

European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation

July 20, 2022

Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

May 31, 2022

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2022 Financial Results

May 4, 2022

Sangamo Therapeutics to Present Data From Its Next-Generation Technologies at 2022 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

May 1, 2022

Sangamo Therapeutics Announces First Quarter 2022 Conference Call and Webcast

April 27, 2022

Sangamo Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of Investigational CAR-Treg Cell Therapy TX200 in Kidney Transplantation

March 28, 2022

Sangamo Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

February 23, 2022

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2021 Conference Call and Webcast

February 16, 2022

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease

February 6, 2022

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo

January 5, 2022

Sangamo Therapeutics Announces Participation at H.C. Wainwright BIOCONNECT Virtual Conference

January 3, 2022

Calls in 2022